ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $59.59 and traded as low as $55.06. ProShares Ultra Nasdaq Biotechnology shares last traded at $55.17, with a volume of 9,601 shares.
The business has a 50 day simple moving average of $53.40 and a two-hundred day simple moving average of $59.59.
The business also recently declared a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd were issued a $0.3964 dividend. This is a positive change from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15. The ex-dividend date was Monday, December 23rd.
A number of large investors have recently modified their holdings of the company. Jane Street Group LLC raised its stake in shares of ProShares Ultra Nasdaq Biotechnology by 8.4% during the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock worth $306,000 after acquiring an additional 374 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 31.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock valued at $270,000 after purchasing an additional 1,266 shares during the last quarter. Finally, Crowley Wealth Management Inc. purchased a new position in ProShares Ultra Nasdaq Biotechnology in the 4th quarter worth $51,000.
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.